We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Sequencing-Based Technology to Deliver ‘Holy Grail’ of Infectious Disease Diagnostics

By LabMedica International staff writers
Posted on 25 Sep 2023

Antimicrobial resistance is a growing global problem that encompasses not just bacterial resistance to antibiotics but also fungal resistance. More...

The overuse of antibiotics has resulted in pathogens becoming resistant to formerly effective medications at a rate that outstrips the creation of new drugs. Treating antibiotic-resistant infections is not only more difficult and costly, but it also typically entails longer hospital stays, extra follow-up consultations, and more expensive, toxic alternative therapies. Such drug-resistant bacteria are increasingly leading to fatal outcomes, particularly in severe infections like sepsis. While timely and appropriate treatment can save lives, existing technologies often don't yield fast enough results for immediate, targeted antibiotic treatment. Moreover, cultures fail to grow in as many as half of all serious bloodstream infections.

Day Zero Diagnostics (Boston, MA, USA) is pioneering a new class of infectious disease diagnostics using the power of whole-genome sequencing and artificial intelligence (AI) to combat the rise of antibiotic-resistant infections. The company is developing a sequencing-based diagnostic that can identify a broad array of bacterial and fungal pathogens while also determining their susceptibility to antimicrobials, all in under eight hours. This is a significant improvement over current methods, which can take days and are associated with an 8% increase in mortality rate for each passing hour.

The company is completing the development of an enhanced Blood2Bac sample preparation protocol that requires smaller sample sizes and is more cost-effective. This protocol is capable of capturing both fungi and bacteria. Day Zero Diagnostics is also fast-tracking the development of a commercial prototype system, incorporating both the hardware and a cloud-based AI algorithm suite called Keynome, which ensures highly accurate identification of organisms and their antimicrobial susceptibility. Hospitals adopting this diagnostic approach can expect reduced lengths of patient stays, minimized use of costly and toxic antibiotics that might not be effective, and most crucially, saved lives.

"DZD is focused on bringing an FDA-cleared diagnostic to market that will deliver the 'holy grail' of infectious disease diagnostics – same day organism identification and antimicrobial susceptibility profiling directly from clinical samples, and our investors share our belief in the game changing nature of our technology," said Jong Lee, CEO and co-founder of Day Zero Diagnostics.

Related Links:
Day Zero Diagnostics


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Microscope
dIFine
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.